127 related articles for article (PubMed ID: 37782911)
1. Potent Antibody Response Elicited by a Third Booster Dose of Inactivated COVID-19 Vaccine in Healthy Subjects.
Ji R; Zhang J; Liang D; Quan H; Wu Y; Peng A; Li W; Lu S; Zhang X; Ke C; Wang D; Xu J
Viral Immunol; 2023 Nov; 36(9):593-599. PubMed ID: 37782911
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
3. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
4. A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days.
Liang XM; Xu QY; Jia ZJ; Wu MJ; Liu YY; Lin LR; Liu LL; Yang TC
Front Immunol; 2022; 13():876037. PubMed ID: 35572536
[TBL] [Abstract][Full Text] [Related]
5. Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
Wen GP; Zhu M; Li LR; Li XJ; Ye HM; Zhou YL
Front Immunol; 2023; 14():1099629. PubMed ID: 36817474
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
7. Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP COVID-19 vaccine.
Cheng ZJ; Huang H; Liu Q; Zhong R; Liang Z; Xue M; Liu M; Li S; Wang H; Zheng P; Zheng C; Sun B
J Med Virol; 2022 Nov; 94(11):5206-5216. PubMed ID: 35801663
[TBL] [Abstract][Full Text] [Related]
8. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
9. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
10. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults.
Wu Y; Huang P; Xu M; Zhao Q; Xu Y; Han S; Li H; Wang Y
Front Immunol; 2023; 14():1152899. PubMed ID: 37559719
[TBL] [Abstract][Full Text] [Related]
12. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
Banga Ndzouboukou JL; Zhang YD; Lei Q; Lin XS; Yao ZJ; Fu H; Yuan LY; Fan XL
Curr Med Sci; 2021 Dec; 41(6):1081-1086. PubMed ID: 34741251
[TBL] [Abstract][Full Text] [Related]
13. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
14. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.
Kugelman N; Nahshon C; Shaked-Mishan P; Kleifeld S; Cohen N; Sher ML; Zahran H; Barsha H; Assaf W; Shalabna E; Stein N; Lavie O; Kedar R; Riskin-Mashiah S
Obstet Gynecol; 2022 Aug; 140(2):187-193. PubMed ID: 35852268
[TBL] [Abstract][Full Text] [Related]
15. Decreasing neutralization antibody levels following vaccination against SARS-CoV-2 in the elderly: an observational study in Southern Moravia, Czech Republic.
Mravčík V; Husa P; Kumpanová Valachovičová S; Vobořil J
Epidemiol Mikrobiol Imunol; 2022; 71(1):9-20. PubMed ID: 35477266
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
Front Immunol; 2022; 13():939311. PubMed ID: 36032136
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort.
Tao Y; Ma M; Hu F; Li M; Geng Y; Wan Y; Mao M; Chen L; Shen Y; Zhu L; Shen H; Chen Y
BMC Immunol; 2022 Nov; 23(1):57. PubMed ID: 36384440
[TBL] [Abstract][Full Text] [Related]
20. The third inactivated vaccine booster dramatically enhanced SARS-CoV-2 antibody responses and did not influence the profile of prothrombotic antibody.
Pan Y; Wang S; Liu G; Wang L; Yang L; Zeng X; Qian C; Lin J; Pan Z; Li Y
J Med Virol; 2023 Jan; 95(1):e28356. PubMed ID: 36443279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
